{"classes":[{"categories":[{"measurements":[{"comment":"NA: more than 50% were either censored or without failure event at time of analysis.","groupId":"OG000","lowerLimit":"9.2","upperLimit":"NA","value":"23.7"},{"comment":"NA: The patient did not have an EFS event at the time of discontinuation.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"EFS is the time from date of tisagenlecleucel infusion to the earliest of death, relapse or treatment failure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"MEDIAN","populationDescription":"FAS: The Full analysis set comprised all patients who received infusion of tisagenlecleucel","reportingStatus":"POSTED","timeFrame":"60 months","title":"Event-free Survival Per IRC Assessment","type":"SECONDARY","unitOfMeasure":"months"}